

METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY

57. A dosage form tablet for treating Attention-Deficit Disorder comprising 100 ng to 500 mg of methylphenidate in admixture with a pharmaceutically acceptable carrier that release the methylphenidate in a sustained and increasing dose for treating Attention-deficit Disorder.

58. A dosage form tablet for treating Attention-Deficit Hyperactivity Disorder, comprising 100 ng to 500 mg of a member selected from the group consisting of methylphenidate and its pharmaceutically acceptable salts mixed with a pharmaceutically acceptable carrier that is delivered in a controlled and increasing dose for treating Attention-Deficit Hyperactivity Disorder.

REMARKS

The specification has been amended, i.e., paragraph [0001], to claim priority to parent application, U.S. Application No. 09/253,317.

Claims 1 and 3-47 have been canceled and claims 48-58 have been added. Upon entry of the Preliminary Amendment, claims 2 and 48-58 should be pending in the above-identified patent application.

Applicants bring to the Examiner's attention withdrawn U.S. Patent No. 6,034,101 (courtesy copy enclosed herewith). The claims previously allowed in U.S. Patent No. 6,034,101 (claims 1-11), are the claims now presented by preliminary amendment. This application claims priority to this withdrawn patent, i.e., U.S. Application No. 08/910,593, filed July 31, 1997.

No new matter has been added by these amendments.

METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY

The Examiner is invited to contact Applicants' Representatives, at the below-listed telephone number, if there are any questions regarding the above new claims or if prosecution of this application may be assisted thereby.

Respectfully submitted,
LAM et al.,
By his Representatives,
ALZA Corporation
1900 Charleston Road
Mountain View, CA 94043
(650) 564-5000

08 March 2001
Date

PBS/KMG

By: Paul B. Simboli
Paul B. Simboli
Reg. No. 38,616
Attorney for Applicants
Direct Dial: (650) 564-7840